William K. Oh, MD
Director, Precision Medicine, Yale Cancer Center and Smilow Cancer HospitalCards
About
Research
Publications
2024
How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening?
Carlsson S, Oh W. How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening? JAMA Oncology 2024, 10: 1497-1498. PMID: 39325462, DOI: 10.1001/jamaoncol.2024.3909.Peer-Reviewed Original ResearchWhat’s in a Name? Why Words Matter in Advanced Prostate Cancer
Oh W, Agarwal N, Bryce A, Barata P, Bugler C, Carlsson S, Cornell B, Dahut W, George D, Loeb S, Montgomery B, Morris D, Mucci L, Omlin A, Palapattu G, Riaz I, Ryan C, Schoen M, Washington S, Gillessen S. What’s in a Name? Why Words Matter in Advanced Prostate Cancer. European Urology 2024, 87: 101-103. PMID: 39472202, DOI: 10.1016/j.eururo.2024.10.017.Peer-Reviewed Original ResearchCriteriaMapper: establishing the automatic identification of clinical trial cohorts from electronic health records by matching normalized eligibility criteria and patient clinical characteristics
Lee K, Mai Y, Liu Z, Raja K, Jun T, Ma M, Wang T, Ai L, Calay E, Oh W, Schadt E, Wang X. CriteriaMapper: establishing the automatic identification of clinical trial cohorts from electronic health records by matching normalized eligibility criteria and patient clinical characteristics. Scientific Reports 2024, 14: 25387. PMID: 39455879, PMCID: PMC11511882, DOI: 10.1038/s41598-024-77447-x.Peer-Reviewed Original ResearchConceptsElectronic health recordsCell lung cancerEligibility criteriaClinical characteristicsLung cancerHealth recordsNon-small cell lung cancerSmall cell lung cancerPatient clinical characteristicsClinical trial cohortPatients' electronic health recordsIdentification of patientsClinical trial criteriaIdentification of eligible patientsSickle cell anemiaNon-alcoholic steatohepatitisStandardized terminologyProstate cancerMultiple myelomaTrial eligibility criteriaPatient selectionTrial cohortBreast cancerEligible patientsTrial criteriaManagement of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Zilli T, Agarwal N, Antonarakis E, Aparicio A, Armstrong A, Bastos D, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon M, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng H, Chi K, Clarke C, Clarke N, de Bono J, De Santis M, Duran I, Efstathiou E, Ekeke O, El Nahas T, Emmett L, Fanti S, Fatiregun O, Feng F, Fong P, Fonteyne V, Fossati N, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman M, Hope T, Horvath L, Hussain M, Jereczek-Fossa B, Jones R, Joshua A, Kanesvaran R, Keizman D, Khauli R, Kramer G, Loeb S, Mahal B, Maluf F, Mateo J, Matheson D, Matikainen M, McDermott R, McKay R, Mehra N, Merseburger A, Morgans A, Morris M, Mrabti H, Mukherji D, Murphy D, Murthy V, Mutambirwa S, Nguyen P, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Rabah D, Rathkopf D, Reiter R, Renard-Penna R, Ryan C, Saad F, Sade J, Sandhu S, Sartor O, Schaeffer E, Scher H, Sharifi N, Skoneczna I, Soule H, Spratt D, Srinivas S, Sternberg C, Suzuki H, Taplin M, Thellenberg-Karlsson C, Tilki D, Türkeri L, Uemura H, Ürün Y, Vale C, Vapiwala N, Walz J, Yamoah K, Ye D, Yu E, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). European Urology 2024, 87: 157-216. PMID: 39394013, DOI: 10.1016/j.eururo.2024.09.017.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceProstate Cancer Consensus ConferenceAdvanced prostate cancerProstate cancerClinical managementLack high-level evidenceConsensus conferenceManagement of patientsHigh-level evidenceEvidence-based guidelinesModified Delphi processCancer characteristicsClinical evidenceClinical trialsImpact daily practiceTreatment decisionsWeb-based surveyConsensus questionsPC expertsPatientsMeta-analysisCancerDelphi processDaily practicePanel membersThe Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART)
Chakrani Z, Patel M, Mellgard G, McCroskery S, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao C, Ganta T, Patel V. The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART). Clinical Genitourinary Cancer 2024, 22: 102227. PMID: 39437664, DOI: 10.1016/j.clgc.2024.102227.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen Receptor AntagonistsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMolecular Targeted TherapyProgression-Free SurvivalProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantReceptors, AndrogenRetrospective StudiesSurvival RateTreatment OutcomeConceptsMetastatic castration-resistant prostate cancerAndrogen receptor-targeted therapiesPSA progression free survivalOverall survivalConcurrent statinSurvival outcomesStatin useSingle-institution retrospective analysis of patientsHazard ratioSingle-institution retrospective analysisCastration-resistant prostate cancerRetrospective analysis of patientsConcurrent statin useAssociation of statin useProgression free survivalReceptor-targeted therapyCox proportional hazards regression modelsOutcomes of patientsAnalysis of patientsMultivariate survival analysisProportional hazards regression modelsTumor cell viabilityMultivariate logistic regressionHazards regression modelsEstimate hazard ratiosPerformance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy
Mellgard G, Saffran N, Chakrani Z, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh W, Tsao C, Patel V. Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy. American Journal Of Clinical Oncology 2024, 47: 459-464. PMID: 39087466, DOI: 10.1097/coc.0000000000001115.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerPerformance statusProstate cancerOverall survivalAndrogen receptor-targeted therapiesCompare overall survivalReceptor-targeted therapyReduced performance statusSingle-institution studyCompare baseline characteristicsAssessment of PSFisher's exact testWilcoxon signed-rank testTaxane chemotherapyShorter OSCompare OSSigned-rank testTargeted therapyTreatment courseAndrogen receptorBaseline characteristicsExact testCox regressionART treatmentOptimizing Clinical Trial Eligibility Design Using Natural Language Processing Models and Real-World Data: Algorithm Development and Validation
Lee K, Liu Z, Mai Y, Jun T, Ma M, Wang T, Ai L, Calay E, Oh W, Stolovitzky G, Schadt E, Wang X. Optimizing Clinical Trial Eligibility Design Using Natural Language Processing Models and Real-World Data: Algorithm Development and Validation. JMIR AI 2024, 3: e50800. PMID: 39073872, PMCID: PMC11319878, DOI: 10.2196/50800.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerClinical trialsLung cancerEligibility criteriaTrial protocolInterventional clinical trialsClinical trial designProstate cancerMultiple myelomaBreast cancerEligible patientsClinical trial protocolsMount Sinai Health SystemCrohn's diseaseUlcerative colitisPatientsPatient identificationSinai Health SystemCancerNatural language processingClinical trial processDelay drug developmentTrial designNatural language processing pipelineSingle-cell transcriptomic-informed deconvolution of bulk data identifies immune checkpoint blockade resistance in urothelial cancer
Wang L, Izadmehr S, Sfakianos J, Tran M, Beaumont K, Brody R, Cordon-Cardo C, Horowitz A, Sebra R, Oh W, Bhardwaj N, Galsky M, Zhu J. Single-cell transcriptomic-informed deconvolution of bulk data identifies immune checkpoint blockade resistance in urothelial cancer. IScience 2024, 27: 109928. PMID: 38812546, PMCID: PMC11133924, DOI: 10.1016/j.isci.2024.109928.Peer-Reviewed Original ResearchScRNA-seqTumor microenvironmentUrothelial cancerRNA sequencingRNA-seq datasetsRNA-seq dataSingle-cellSingle-cell RNA sequencingMinor cell typesCohorts treated with immune checkpoint inhibitorsResistance to immune checkpoint blockadeImmune checkpoint blockade resistanceCheckpoint blockade resistanceImmune checkpoint blockadeImmune checkpoint inhibitorsTumor microenvironment heterogeneityFeatures associated with poor outcomeSpatial genomicsHuman urothelial cancerInfluence tumor progressionClinically relevant insightsCheckpoint blockadeCheckpoint inhibitorsTreatment responseCell typesProstate Cancer Foundation Screening Guidelines for Black Men in the United States.
Garraway I, Carlsson S, Nyame Y, Vassy J, Chilov M, Fleming M, Frencher S, George D, Kibel A, King S, Kittles R, Mahal B, Pettaway C, Rebbeck T, Rose B, Vince R, Winn R, Yamoah K, Oh W. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States. NEJM Evidence 2024, 3: evidoa2300289. PMID: 38815168, DOI: 10.1056/evidoa2300289.Peer-Reviewed Original ResearchConceptsProstate-specific antigenBaseline PSA testingProstate-specific antigen screeningPSA testingProstate cancerScreening guidelinesBlack menBaseline prostate-specific antigenProstate-specific antigen valuesYears of follow-upProstate cancer deathProstate cancer mortalityScreening of menFull-text reviewComprehensive literature searchRandomized controlled trialsNon-black menAnnual screeningFrequency of testingIncrease overdiagnosisFollow-upProstateCohort studyCancer mortalityUnited StatesHigher fluid and lower caloric intakes: associated risk of severe bronchopulmonary dysplasia in ELBW infants
Kolitz D, Przystac L, Tucker R, Oh W, Stonestreet B. Higher fluid and lower caloric intakes: associated risk of severe bronchopulmonary dysplasia in ELBW infants. Journal Of Perinatology 2024, 44: 941-946. PMID: 38459372, DOI: 10.1038/s41372-024-01928-0.Peer-Reviewed Original ResearchConceptsSevere bronchopulmonary dysplasiaBronchopulmonary dysplasiaCaloric intakeELBW infantsOdds of bronchopulmonary dysplasiaGeneralized estimating equationsAssociated with increased riskMultiple logistic regression analysisLow caloric intakeLogistic regression analysisMean fluid intakeLogistic regression modelsFluid intakeIncreased riskDesignCase-control studyZ-scoreInfantsIntake profileLinear growthELBWZ score pointIntakeDysplasiaWeeksRegression analysis
Clinical Care
Overview
William K. Oh, MD, is a genitourinary oncologist with decades of experience specializing in prostate cancer. He integrates molecular and genetic testing into routine cancer care, ensuring that patients receive the most personalized treatment plans possible. Throughout his career he has focused on decreasing barriers to the delivery of care for prostate cancer nationally.
Dr. Oh is the director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital, where he leads efforts to develop cohesive programs that combine basic and translational science with clinical trials. He also oversees the Precision Medicine Tumor Board, which is pivotal in guiding treatment decisions based on genetic and molecular data. Additionally, he serves as the service line medical director of Smilow Cancer Hospital at Greenwich Hospital, where he continues to develop integrated oncology care teams and expand the impact of multidisciplinary cancer care for patients in the region.
Dr. Oh completed his undergraduate degree at Yale University, received his medical degree from New York University School of Medicine, and did his internship and residency at Brigham and Women’s Hospital before his clinical fellowship in medical oncology at Dana-Farber Cancer Institute.
Dr. Oh currently serves as chair of the American Cancer Society's National Prostate Cancer Roundtable, whose mission is to improve prostate cancer outcomes and survivorship through increasing awareness and equitable access to prevention, screening, and treatment. Also, he is the chair of the Medical Advisory Council for the Chemotherapy Foundation, which is committed to discovering novel therapies for cancer.
“I love taking care of patients because it brings me tremendous personal satisfaction to both help them and learn from them,” Dr. Oh says. “I also love the precision medicine part of my job, but in the end, my patient care responsibilities always bring me back to what it’s all about and why we’re all here and I enjoy getting to know my patients and their generosity of spirit and courage. I take a lot of lessons from that.”
Clinical Specialties
Fact Sheets
Prostate Cancer
Learn More on Yale MedicineUrologic Cancers
Learn More on Yale Medicine
Yale Medicine News
News & Links
Media
New Advances in Prostate Cancer in 2025
Yale Cancer Center Grand Rounds | January 21, 2025
Presented by: Dr. William Oh
News
- April 15, 2025Source: YaleMedicine.org
Understanding Cancer Language: Tumor Terms Patients Should Know
- March 27, 2025
Prostate and Urologic Cancers Program at Smilow Cancer Hospital at Greenwich
- January 21, 2025
Yale Cancer Center Experts Lead National Roundtables
- November 22, 2024Source: The Cancer Letter
William Oh named service medical director at Smilow Cancer Hospital at Greenwich
Get In Touch
Contacts
Yale Cancer Center
333 Cedar Street, PO Box 208028
New Haven, Connecticut 06520
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
- EveryoneMulti-session Event